Compare Medpace Holdings Inc (MEDP) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs iShares Silver Trust — how do they compare? Medpace Holdings Inc trades at $615.78 (market cap $16.82B), while iShares Silver Trust trades at $54.9 (market cap $29.02B). The key difference: iShares Silver Trust is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and iShares Silver Trust for 89 Days on average.
| MEDP | SLV | |
|---|---|---|
Market Cap | $16.82B | $29.02B |
Volume | 223,093 | 16,510,334 |
Sector | Health | — |
52-Week High | $630.19 | $105.57 |
52-Week Low | $393.42 | $42.40 |
Typical Hold Time | 14 Days | 89 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
SLV trades at $55.06, up 2.3% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported $2.17M net income for 2024 despite zero revenue, with total assets surging to $13.41B from $10M in 2023. Recent news highlights silver price volatility driven by Fed policy expectations and Treasury yields.
The outlook is clouded by bearish technicals and macroeconomic pressures on silver, though low debt and asset growth offer stability. Risks include interest rate sensitivity and industrial demand fluctuations, while institutional sentiment remains cautious amid price declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
